



Organisation  
of European  
Cancer Institutes

[ecancermedicalscience](http://ecancermedicalscience)

Official OECI Journal



ESO  
Recommended

# Oncology Days

OECI 39

# BRNO 2017

## GENERAL ASSEMBLY, SCIENTIFIC CONFERENCES AND RELATED EVENTS

*Brno, Czech Republic  
June 21<sup>st</sup>-23<sup>rd</sup> 2017  
Hotel International*

**10<sup>th</sup>**  
**ANNIVERSARY**  
**Oncology**  
**Days**



FINAL  
PROGRAMME

**OECI**  
INNOVATIVE  
HIGH-QUALITY  
**CANCER CARE**  
THROUGH  
COORDINATING  
**RESEARCH AND**  
**EDUCATION**

## President's address

### Welcome to OECI Oncology Days 2017

For the first time, the annual convention of the Directors of the European Cancer Institutes is taking place in Brno, hosted by the Masaryk Memorial Cancer Institute and the Institute of Biostatistics and Analyses of the Masaryk University. I would like to thank our hosts in Brno, on behalf of all our Members, for the generous support given to this event and for the great opportunity to learn more about the Czech Republic's approach to a more harmonised organisation of cancer care through the creation of a network at a regional level.

The OECI Oncology Days debut was in Genoa in 2008, almost 10 years of an event, which has become a "not-to-be missed" gathering of the main European actors in cancer care.

Our expertise in certification of quality, promoted by means of our Accreditation and Designation Programme, is increasingly well-established and has been called upon recently, in order to help define quality criteria within the Joint Action on Rare Cancers, which operates in synergy with the set-up of European Networks of Reference Centres for Rare Cancers.

During the past year, we have continued to build upon our strategic alliance with the European Cancer Patient Coalition, and the first joint action on "Engaging Patients in Clinical Research" has been presented and launched at ECCO 2017 in Amsterdam.

The increase in survivorship has also reinforced the issue of patient rights to access a dignified and active life in society post illness, on top of the best options for cure and therapeutic solutions. We look forward to collaborating with you and our Patient counterpart, the ECPC, and to sharing with you, in the near future, the outcomes of our joint pilot projects, which will be actively undertaken by the OECI's new working group: Collaboration for Good Practices with Patients.

The ongoing restructuring of the Supportive and Palliative Care Working Group is also another OECI way of involving our hospitals in the enormous increase of cancer prevalence that poses crucial problems for the oncologists and to the health systems, unable to face the increasing cost of care.

For the above reasons, and upon the suggestion of our Brno colleagues, who are deeply involved in this topic, we decided to focus the **2017 Scientific Conference on "Rising cancer prevalence as emerging challenge for oncologists"**, debating the growing issue, outcomes opportunities, and how to address specific needs.

**The 2017 Pathology Day** will be debating on how to standardise methods for testing circulating cell free DNA; a huge potential not only for research but also for clinical diagnostics, especially in recurrent tumours. A preliminary technical, common protocol for plasma ccfDNA will be presented to reach a consensus amongst OECI experts and to adopt specific standards in a reproducible manner to be used for clinical investigations through European cancer centres.

The 2017 Oncology Days marks the 39th convening of the Directors of European Cancer Centres, members of OECI. This is a solid example of the dedication and efforts made by the OECI and its Members in the promotion of sustainable progress, with the aim of improving the level of care, by giving patients, from all walks of life, equal access to the best quality in cancer care.

The OECI is honored to be in Brno, in the heart of Europe, at the Masaryk Memorial Cancer Institute, one of the founders of our Organisation.

Have a pleasant stay and constructive interactions during these OECI 2017 Oncology Days.

**Dominique de Valeriola**  
OECI President



# OECI2017 ONCOLOGY DAYS

## Masaryk Memorial Cancer Institute Director's welcome

Dear OECI colleagues and friends,

It is a great honor for us to welcome you in Brno, the second largest city of the Czech Republic, where the Masaryk Memorial Cancer Institute (MMCI) is located.

The MMCI holds a leadership position in providing health care services and research in the areas of prevention, diagnosis and treatment of solid tumors in the Czech Republic. The MMCI, which was the founding member of the OECI in 1979, considers this Organisation an important partner, which still inspires us in creating our own development strategies. That is why we have chosen the OECI Accreditation and Designation Programme instead of the previous JCI accreditation, as an instrument to maintain high quality of care in our Institute.

We are delighted by the OECI decision to choose Brno as a place for the 39<sup>th</sup> Oncology Days and MMCI as co-organiser of the event. In addition to the conference, all participants are invited to visit our Institute and some interesting places of our City and Region, e.g. the Augustinian cloister with the museum where Gregor Mendel discovered the rules of inheritance.

We hope that you will find the City of Brno a pleasant and friendly place for the OECI Oncology Days 2017.



**Prof. Jan Žaloudik**  
MMCI Director

A handwritten signature in black ink, which appears to be 'J. Žaloudik', written over a stylized, light blue graphic element that resembles a signature or a decorative flourish.

## Introduction to the OECI

The OECI is a non-governmental, non-profit Organisation founded in Vienna in 1979 and remodeled in 2005 into OECI-EEIG, a European Economic Interest Grouping, headquartered in Brussels.

The OECI is a network of cancer Institutions established to create a critical mass of expertise and competences, contributing to the production and dissemination of knowledge, so as to reduce fragmentation and increase competitiveness. These goals are being achieved by promoting and strengthening the concept of “comprehensiveness”, supporting quality in cancer care also through a well-structured internal organisation. In an effort to efficiently contribute towards an increase in the quality of care, more than 50% of all OECI Members are already participating in the OECI Accreditation & Designation Programme.

OECI aims to accelerate the production and application of personalised care approaches, and to ensure equal rights to all cancer patients, with the ultimate goal of finding new and better treatments, providing more comprehensive care and improving patient quality of life, through evidence-based medicine. To better achieve its goals, the Organisation works in close collaboration with the European Cancer Patients Coalition.

Today, the OECI counts 78 Member Institutes, which include some of the most prominent European Comprehensive Cancer Centres dynamically working in crosscut expertise projects organised by involving the OECI Working Groups, Activities and Members. The common goal is to facilitate member participation in European projects and programmes, to support training activities on forefront topics, which provides a sound basis for accelerated development of expertise and future collaborative work. This in turn attracts professionals and officers from across disciplines and ultimately underlines the value of multidisciplinary actions.

Giving the crucial role to pathology departments in oncology and the expected “influx” of new markers and diagnostics, the OECI acts in close cooperation with the European Association for Cancer Research and the European Society of Pathology, in order to better disseminate the innovation process amongst its members and abroad.

The dissemination of the OECI activities, reports, proceedings are publicised through the OECI website at <http://www.oeci.eu> and [ecancermedicalsience](http://www.ecancer.org), the Official OECI e-Journal at <http://www.ecancer.org>

The main OECI events are also announced on Cancerworld and on Tumori Journal.



**Cancerworld**

# OECI2017 ONCOLOGY DAYS

## Why join the OECI?

### The advantages of being and of becoming an OECI Member

#### General opportunities

- Support for both the professional development of your Institute and the advancement of European cancer research and care, politically, economically and scientifically
- Representation and advocacy at the highest levels of European cancer policy discussion as a founding member of ECCO, the European Cancer Organisation
- Make contact with other Cancer Centres through the OECI Member Directory, meetings, job and research opportunities, partnership in research applications.
- Possibility to send a nomination to be elected into the OECI Board (only for full Members)
- Active participation in the activities of all the OECI Working Groups and activities:
  - Accreditation and Designation
  - Biobanks and Molecular Pathobiology
  - Cancer Economics and Benchmarking
  - START-OECI – State of ART oncology in Europe
  - Cancer Outcomes Research
  - Supportive and Palliative Care
  - Collaboration for Good Practices with Patients
- Propose a new Working Group
- Promote your Institute using the OECI logo on the local website, letterhead, publications and initiatives.

#### Accreditation and Designation

- Access to the OECI Programme for the certification of your Institute as a Clinical Cancer Centre or a Comprehensive Cancer Centre (restricted to OECI Members)
- Participation in the revisions of the A&D standards every five years.

#### EC Applications

- Join as partner in EC research/training applications coordinated by OECI or by other promoters.

#### Congresses, training and education

- No registration rates for the staff of OECI members interested in attending the OECI Annual event “Oncology Days” including participation in the Scientific Conference, the Pathology Day, the Gala Dinner and all the other scientific and social activities
- Annual, free registration for OECI members to one selected course of interest that is part of the ESO training programme

# OECI2017 ONCOLOGY DAYS

- Reduced fee to participate in the OECI-EACR Conference series on Molecular Pathology and Precision Medicine
- Possibility for your staff to apply for a free registration and to a maximum of 500 Euros travel support for OECI-EACR Conference series
- Reduced fee to participate in ecancer organised events
- Reduced fee to participate in the ECCO congress
- Promotion and dissemination through OECI webnews, and regular email bulletins, of local level organised International congresses and training courses.

## Publication and Dissemination

- Inclusion of the main information and references of your Institute in the OECI webpages and in the Annual OECI Yearbook, widely disseminated in Europe.
- Easy access to publish original papers in ecancer, the official OECI Journal
- The opportunity to film and document your centre's work by ecancer
- Free subscription to receive printed copies of Cancerworld and Tumori Journal
- Publication of news related to your Institute on the biannual OECI Magazine
- Open forums and links on the OECI website
- Receiving regularly copies of OECI printed materials and Certificate of Membership.

## OECI Cancer Prize

- Open nominations to the prestigious award, the "OECI Oncology Prize", awarded biennially in a specific field of cancer research and care to an OECI related scientist. The Prize is delivered by Her Royal Highness the Princess Astrid of Belgium.





# OECI2017 ONCOLOGY DAYS

## The OECI Board



**President**  
Dominique de Valeriola  
Brussels, Belgium



**Executive Secretary**  
Marco A. Pierotti  
Milan, Italy



**Former President**  
Wim H. van Harten  
Amsterdam, The Netherlands



**Treasurer**  
José Maria Laranja Pontes  
Porto, Portugal



**Elected Member**  
Carlos Caldas  
Cambridge, United Kingdom



**Elected Member**  
Christof von Kalle  
Heidelberg, Germany



**Elected Member**  
József Lövey  
Budapest, Hungary



**Elected Member**  
Gunnar Sæter  
Oslo, Norway



**Elected Member**  
Thierry Philip  
Paris, France



**OECI Director**  
Claudio Lombardo  
Brussels, Belgium - Genoa, Italy



**OECI Central Office**  
Guy Storme  
Brussels, Belgium

## Working Groups and Activities



**Accreditation and Designation**  
Simon Oberst  
Cambridge, United Kingdom



**Collaboration for Good Practices with Patients**  
Dominique de Valeriola  
Brussels, Belgium



**Biobanks and Molecular Pathobiology**  
Giorgio Stanta  
Trieste, Italy



**START-OECI**  
Lisa Licitra  
Milan, Italy



**Cancer Economics and Benchmarking**  
Wim H. van Harten  
Amsterdam, The Netherlands



**Communication and Dissemination**  
Gordon McVie  
Milan, Italy



**Cancer Outcomes Research**  
Milena Sant  
Milan, Italy



Claudio Lombardo  
Brussels, Belgium  
Genoa, Italy



**Supportive and Palliative Care**  
Pending





# OECI2017 ONCOLOGY DAYS

## The OECI membership

### Austria

- **Comprehensive Cancer Center Graz**, Graz
- **Comprehensive Cancer Center Vienna**, Wien
- **Zentrum für Tumorerkrankungen Linz** Onkologisches Leitspital für Oberösterreich, Linz


### Belgium

- ★ **Institut Jules Bordet (IJB)**, Brussels 
- ★ **Kankercentrum Brussel**, Brussels 
- ★ **AZ Groeninge**, Kortrijk
- **Institut Roi Albert II**, Brussels

### Croatia

- **Klinika za tumore Klinicki bolnicki centar Sestre milosrdnice**, Zagreb

### Czech Republic

- ★ **Masarykuv onkologický ústav**, Brno 
- **Institut biostatistiky a analýz Lékařské a Přírodovědecké fakulty Masarykovy university**, Brno


### Denmark

- ★ **Vejde Sygehus-Patienternes Kræftsygehus**, Vejle 
- **Kræftens Bekæmpelse Center for Kræftforskning**, Copenhagen

### Estonia

- ★ **Sihtasutus Tartu Ülikooli Kliinikum**, Tartu 
- **North Estonia Medical Centre**, Tallin

### Finland

- ★ **HYKS Syöpäkeskus Helsinki University**, Helsinki 
- ★ **Tampere University Hospital**, Tampere
- **TYKS Syöpäkeskus**, Turku

### France

- ★ **Gustave Roussy**, Villejuif 
- ★ **Centre Léon Bérard**, Lyon 
- ★ **Institut Curie**, Paris
- **Centre de Lutte Contre le Cancer Paul Strauss**, Strasbourg
- **Centre Henri Becquerel**, Rouen

### Germany

- **Deutsches Krebsforschungszentrum (DKFZ)**, Heidelberg
- **Universitäts KrebsCentrum Dresden**, Dresden
- **Charité Comprehensive Cancer Centre**, Berlin

### Hungary

- ★ **Országos Onkológiai Intézet**, Budapest
- **Országos Korányi TBC és Pulmonológiai Intézet**, Budapest

### Italy

- ★ **Centro di Riferimento Oncologico, Istituto Nazionale Tumori**, Aviano 
- ★ **IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale per la Ricerca sul Cancro**, Genova 
- ★ **Istituto Europeo di Oncologia**, Milano 
- ★ **Fondazione IRCCS Istituto Nazionale dei Tumori di Milano**, Milano 
- ★ **Istituto Nazionale Tumori Regina Elena**, Roma 
- ★ **Istituto Oncologico Veneto IRCCS-IOV**, Padova 
- ★ **IRCCS Istituto Clinico Humanitas**, Milano 
- ★ **Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico**, Bari 
- ★ **Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale)**, Napoli 
- ★ **IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB)**, Rionero in Vulture 
- ★ **Azienda Ospedaliera Arcispedale S. Maria Nuova IRCCS Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia**, Reggio Emilia 
- **Ospedale S. Raffaele (OSR)**, Milano

- **European School of Oncology (ESO)**, Milano
- **IFOM - FIRC Institute of Molecular Oncology**, Milano
- **Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [IRST]-IRCCS**, Meldola - Forlì
- **IRCCS - Istituto di Ricerche Farmacologiche Mario Negri**, Milano
- **Ente Ospedaliero Ospedali Galliera**, Genova
- **Nerviano Medical Sciences Group S.r.l.**, Nerviano
- **IRCCS Istituto Dermovenereologico S. Maria e S. Gallicano**, Roma

## Lithuania

- ★ **National Cancer Institute**, Vilnius 

## Norway

- ★ **Oslo Universitetssykehus (OUS)**, Oslo 

## Poland

- **Wielkopolskie Centrum Onkologii**, Poznań

## Portugal

- ★ **Instituto Português de Oncologia do Porto Francisco Gentil E.P.E. (IPO-Porto)**, Porto 
- ★ **Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa)**, Lisbon 
- ★ **Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E.(IPO-Coimbra)**, Coimbra 

## Romania

- ★ **The “Prof. Dr. Ion Chiricuta” Institute of Oncology (IOCN)**, Cluj
- **SC RTC Radiology Therapeutic Center – Amethyst Radiotherapy**, Otopeni

## Russia

- **Tatarstan Cancer Center “TCC”**, Kazan
- **N.N. Blokhin Russian Cancer Research Centre**, Moscow
- **P.A. Herzen Moscow Cancer Research Institute**, Moscow

## Serbia

- **Oncology Institute of Vojvodina**, Sremska Kamenica

## Slovakia

- **Ústav experimentálnej onkológie SAV**, Bratislava

## Slovenia

- **Onkološki inštitut Ljubljana**, Ljubljana

## Spain

- ★ **Fundación Instituto Valenciano de Oncología IVO**, Valencia 
- **Institut Català d'Oncologia**, L'Hospitalet de Llobregat - Barcelona
- **Instituto Madrileño de Oncología (Grupo IMO)**, Madrid

## Sweden

- **Karolinska Institute and University Hospital**, Stockholm
- **Skåne University Hospital South Western Cancer Centre**, Malmö

## The Netherlands

- ★ **Netherlands Cancer Institute**, Amsterdam 
- **Erasmus MC Cancer Institute**, Rotterdam
- **IKNL Integraal Kankercentrum Nederland**, Utrecht
- **Maastricht University Medical Centre**, Maastricht
- **Radboudumc Centrum voor Oncologie**, Nijmegen
- **Rijnstate Hospital Arnhem**, Arnhem

## Turkey

- ★ **Anadolu Saglik Merkezi (Anadolu Medical Center)**, Kocaeli
- **Dokuz Eylul Üniversitesi Onkoloji Enstitüsü**, Izmir

## Ukraine

- **RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (IEPOR)**, Kyiv

## United Kingdom

- ★ **The Christie NHS Foundation Trust**, Manchester 
- ★ **Cambridge Cancer Centre**, Cambridge 
- ★ **King's Health Partners Integrated Cancer Centre**, London 
- **Imperial College Healthcare NHS Trust**, London

#### Description of the Institute

Masaryk Memorial Cancer Institute (MMCI) is the healthcare provider, research institution and teaching hospital, designated by Ministry of Health of the Czech Republic as a Czech comprehensive cancer center for patients with solid tumors. The MMCI plays the role of the national cancer institute and is the only one regular representative of the Czech Republic in the OECD, of which has been one of the founding members. In fulfilling its mission, MMCI cooperates with many domestic and foreign organisations and belongs to the European network of research infrastructures. The MMCI is accredited by the Czech Joint Accreditation Commission and currently is undergoing a process of the OECD designation and accreditation.

The MMCI was founded in January 1935 and is named after one of its founders, the first Czechoslovak president T. G. Masaryk. The other leading personalities of the Institute at the time its formation were: dr. Jaroslav Bakeš, significant Czech surgeon, professor Richard Werner, a former director of the cancer institute in Heidelberg, who was appointed to the post of the head of the clinical section, and professor Vladimír Moravěk, the biochemist, who was the head of the laboratory and research section of the institute. The development of Institute always reflected the progression in treatment and research of cancer. In the 1960s, in addition to radiation therapy and surgery, chemotherapy and immunotherapy started to be applied in experimental practice in the institute. Under the leadership of prof. Švejda the MMCI became one of the founding members of OECD in the 1970's. Since 1976, the Institute had regularly been organising the most significant Czech Oncology Conference: "Brno Oncology Days", which is regularly attended by more than 1,600 participants in last 5 years. At the





present, the institute focuses on the treatment of adult patients with solid tumors, but in the field of radiotherapy and laboratory methods provides its services also for patients from other university hospitals, in which the treatment of haematological malignancies and pediatric cancers is concentrated.

The institute currently has 256 hospital beds and an extensive outpatient complement. Every year, the Institute has treated approximately 5 000 of newly diagnosed cancer patients and hospitalised nearly 10,000 patients. The total number of outpatient visit always exceed 160 000. In our patients, more than 350,000 radiotherapy interventions, 23,000 applications chemotherapy and targeted therapies, nearly 5,000 surgical procedures and more than 6,000 endoscopic procedures are performed. The Institute is the largest radiotherapeutic center in the Czech Republic, has 7 linear accelerators. Our patients have access to state of the art treatment approaches in all areas of cancer treatment, including robotic surgery, stereotactic radiotherapy and radiosurgery, targeted anticancer therapy and immunotherapy.

### **Clinical Facilities**

Department (Dpt.) of Comprehensive Cancer Care, Dpt. of Radiation Oncology, Dpt. of Surgical Oncology, Dpt. of Urologic Oncology, Dpt. of Gynecologic Oncology, Dpt. of Gastroenterology and Endoscopy Centre, Dpt. of Epidemiology and Tumor Genetics, Dpt. of Clinical Evaluations and Phase I/II Unit, Dpt. of Anesthesiology and Intensive Care, Dpt. of Nuclear Medicine and PET/Cyclotron Centre, Dpt. of Radiology, Dpt. of Laboratory Medicine, Dpt. of Oncological Pathology, Dpt. of Clinical Psychology, Pharmacy, Specialised Outpatients Clinics.

### **Main research activities**

The MMCI is a Czech unique center which concentrates basic and applied cancer research. Most of the basic and translational research is carried out through our separate research facility called RECAMO (Regional Centre for Applied Molecular Oncology). The MMCI is a Czech node of BBMRI-ERIC (Biobanking and Biomolecular Resources Research Infrastructure) and in the field of clinical research, the Institute has own clinical phase I/II unit and is a partner of the Czech Clinical Research Infrastructure Network (CZECRIN), by which the Czech Republic is represented in ECRIN-ERIC.

The MMCI main research programmes include:

1. Proteomics,
2. Tumours and viruses,
3. Molecular biomarker discovery and evaluation,
4. Cancer Stem Cells and p53 protein family,
5. Chaperones and metabolism,
6. Cancer immunity and angiogenesis,
7. Cellular signalisation and cancer,
8. Molecular diagnostics,
9. Hereditary defects in cancer,
10. Molecular imaging,
11. Noncoding RNAs.

### **Education**

MMCI is a teaching hospital affiliated with Masaryk University ([www.muni.cz](http://www.muni.cz)) and its Faculty of Medicine, thus pre- and postgraduate education and training is carried out in the Institute. The Institute is also involved in continual medical, nursing and pharmaceutic education in oncology.

## The OECI 2017 Oncology Days

### Oncology Days programme

Tuesday June 20<sup>th</sup> - 19.45

Hotel International Brno – Restaurant Lobby

- **Welcome Drink and Pathology Dinner**
- 

Wednesday June 21<sup>st</sup> - All day

Hotel International Brno – Lecture Hall D

- **Pathology Day**

**N-1 trial consortium: collaboration among oncologists, pathologists, bioinformaticians and ethics experts**

---

Wednesday June 21<sup>st</sup> - 13.30-15.30

A&D Board (Restricted to OECI A&D Board Members)

Hotel International Brno – Hall 6

- **Accreditation and Designation Board**
- 

Wednesday June 21<sup>st</sup> - 16.00-18.00

Hotel International Brno – Meeting room 3

- **Accreditation & Designation Session**

**Developing Quality Criteria for Comprehensive Cancer networks: what makes a great cancer network?**

---

Wednesday June 21<sup>st</sup> - 19.00

- **Visit to the Mendel Museum and light refreshment**
- 

Thursday June 22<sup>nd</sup> - All Day

Hotel International Brno – Lecture Hall A

- **Scientific Conference**

**Rising cancer prevalence as emerging challenge for oncologists**

---

Thursday June 22<sup>nd</sup> - 17.30-18.30

Hotel International Brno – Hall A

- **Working Group Meeting**

**Launch of Collaboration for Good Practices with Patients WG (CGPP)**

---

Thursday June 22<sup>nd</sup> - Evening

- **Gala Dinner at Špilberk Castle**

(Restricted to members and upon invitation)

---

Friday June 23<sup>rd</sup> - Morning

Hotel International Brno – Lecture Hall D

- **OECI General Assembly 2017**

(Restricted to OECI Member Representatives or Delegates)

## General timetable

	20 June 2017	21 June 2017	22 June 2017	23 June 2017
MORNING		<p><b>OECI Pathology Day</b>                      N-1 trial consortium: collaboration among oncologists, pathologists, bioinformaticians and ethics experts                      Hotel International Brno                      Lecture Hall D</p>	<p><b>Scientific Conference</b>                      Rising cancer prevalence as emerging challenge for oncologists                      Hotel International Brno                      Lecture Hall A</p>	<p><b>OECI 2017 General Assembly</b>                      Hotel International Brno                      Lecture Hall D</p>
		Lunch	Lunch	Lunch
AFTERNOON	<p><b>Board and Extended Board Meeting</b>                      Hotel International Brno                      Meeting room 3</p>	<p><b>OECI Pathology Day</b>                      N-1 trial consortium: collaboration among oncologists, pathologists, bioinformaticians and ethics experts                      Hotel International Brno                      Lecture Hall D</p> <p><b>Accreditation and Designation Session</b>                      Developing Quality Criteria for Comprehensive Cancer networks: what makes a great cancer network?                      Hotel International Brno                      Meeting room 3</p>	<p><b>Scientific Conference</b>                      Rising cancer prevalence as emerging challenge for oncologists                      Hotel International Brno                      Lecture Hall A</p> <p><b>WG Meeting</b>                      Launch of Collaboration for Good Practices with Patients WG (CGPP)</p>	
EVENING	<p><b>Extended Board and Pathology Dinner</b></p>	<p><b>Visit to the Mendel Museum and Light refreshment</b></p>	<p><b>Gala Dinner</b></p>	



## OECI Pathology Day

### **N-1 trial consortium: collaboration among oncologists, pathologists, bioinformaticians and ethics experts**

**June 21<sup>st</sup>**

**Hotel International  
Brno**

**Lecture Hall D**

The 2017 Pathology Day has been designed also for oncologists, molecular biologists, epidemiologists, bioinformaticians. The N-1 trials will be discussed, as well as the possibility that the OECI can be the basis of the largest possible N-1 trials consortium. The OECI Biobanks and Molecular Pathobiology WG started some initiatives to develop a specific consortium on N-1 trials. Two meetings have been carried out in the campus of the Centro di Riferimento Oncologico in Aviano, with the collaboration of ATMA Expert Centre (BBMRI-ERIC), to study standardised protocols on plasma DNA analysis and fixed and paraffin embedded tissues NGS Whole Exome Sequences.

Two protocols will be preliminarily presented at the 2017 Pathology Day in order to develop a specific collaboration among OECI Members, and taking into account bioinformatics and ethical aspects.

N-1 trials appear to be the best solution to apply in a shorter time new treatments to patients, with a continuous development in the clinical experience. The basic needs for this type of consortium is the collection of a very large amount of patients' information.

#### Session 1

##### **INTRODUCTION**

9.45 *Chair: Dalibor Valik and Giorgio Stanta*

10.00 **Introduction to the organisation of the consortium**

*Giorgio Stanta*

10.20 **N-1 trials: can they help in personalised precision oncology?**

*Dalibor Valik*

10.40 **New types of treatment in "rare tumors"**

*Manfred Dietel*

11.00 **Discussion**

#### Session 2

##### **TECHNICAL ORGANISATION OF THE NETWORK**

*Chair: Marco Pierotti and Giorgio Stanta*

11.20 **SPIDIA4P: preanalytical conditions of tissues**

*Serena Bonin*

11.40 **Sequencing from clinical tissues. Possibility of standardised technical protocols and interpretation**

*Ivo Gut*

12.00 **Liquid biopsies: plasma DNA standardised protocol**

*Andreas Jung*

12.20 **Discussion**

## OECI Pathology Day

### **N-1 trial consortium: collaboration among oncologists, pathologists, bioinformaticians and ethics experts**

**June 21<sup>st</sup>**

Hotel International  
Brno

Lecture Hall D

13.00 Lunch

#### Session 3

##### BIOINFORMATICS

Chair: *Manfred Dietel and Gianluigi Zanetti*

14.00 **Possibility to organise a neutral bioinformatics hub for the collection of data**

*Gian Luigi Zanetti*

14.20 **Exploration of hospital-based clinical databases: outcome-based approach bridging evidence based medicine and real world evidence**

*Ladislav Dušek*

14.40 **BBMRI-ERIC: New bioinformatics tools for European Biobank network: a practical implementation of FAIR principle**

*Petr Holub*

15.00 **Discussion**

#### Session 4

##### BIOETHICAL IMPLICATIONS

Chair: *Francesco De Lorenzo and Marialuisa Lavitrano*

15.20 **Ethical implications in wide collection and sharing of clinical data**

*Francesco Florindi*

15.40 **New European rules for clinical data management**

*Marialuisa Lavitrano*

16.00 **Discussion**

16.20 Coffee Break

#### Session 5

17.00-19.00 **ROUND TABLE ABOUT OECI CONSORTIUM DEVELOPMENT**

Chair: *Marco Pierotti and Giorgio Stanta*

## Accreditation and Designation Working Group Session

### Developing Quality Criteria for Comprehensive Cancer networks: what makes a great cancer network?

**June 21<sup>st</sup>**  
Hotel International  
Brno  
Meeting room 3

In this session we are seeking to articulate what the quality criteria are for effective patient-centred cancer networks. That applies to common cancers where specialist services such as specialist surgery are only provided in the comprehensive hub of the network, and to networks of rare cancers, where issues of referral, second opinions and cross-border care are vital. We also consider the question of how practice changing research feeds into the life of the network.

- 16.00 **Introduction to the policy issues on networks as viewed by OECD**  
*Simon Oberst*
- 16.20 **Comprehensive Cancer Care Networking (CCCN) as effective cancer management model: pilot project of the Czech Republic**  
*Ladislav Dušek*
- 16.50 **Cancer Care System and Healthcare management in the Russian Federation**  
*Khayrullin Ildar*
- 17.10 **Pathway Benchmarking in Networks - relating outcomes to organisation**  
*Wim Van Harten*
- 17.40 **Discussion**

## Scientific Conference Rising cancer prevalence as emerging challenge for oncologists

June 22<sup>nd</sup>

Hotel International  
Brno

Lecture Hall A

### Session 1 **Prevalence, a growing issue**

Chair: *Gemma Gatta* Co-chair: *Ladislav Dusek*

- 09.00 **Introduction** *Gemma Gatta*  
09.20 **Epidemiology: dimension, trends, future projections** *Emanuele Crocetti*  
09.40 **Prevalence of breast cancer** *Etienne Brain*  
10.00 **Cancer survivors, phase-specific problems and needs** *Sophie D. Fossa*  
10.20 **Prevalence of prostate cancer** *Nicola Nicolai*
- 10.40 **Conclusions**

Coffee Break

### Session 2 **Real World: Outcomes Surveillance**

Chair: *Milena Sant* Co-chair: *Rostislav Vyzula*

- 11.20 **Introduction and illustration of the OECI study proposal/feed-back of the survey on outcome studies** *Milena Sant*  
11.40 **Comorbidity affecting breast cancer prognosis and cure** *Branko Zacotnik*  
12.00 **Quality of life in cancer survivors** *Luzia Travado*  
12.20 **Cancer Outcomes and social deprivation** *Camille Maringe*  
12.40 **Clinical registries in cancer centres** *Antoniette de Vries*
- 13.00 **Conclusions**

Lunch

### Session 3 **Addressing needs**

Chair: *Dominique de Valeriola* Co-chair: *Marek Svoboda*

- 15.00 **Introduction** *Dominique de Valeriola*  
15.20 **The patient's perspective** *Francesco De Lorenzo*  
15.40 **The economist's perspective** *Richard Sullivan*  
16.00 **Handling rare cancers** *Annalisa Trama*  
16.20 **The CanCon Joint Action conclusions** *Tit Albreht*
- 16.40 **Conclusions**

# OECI2017 ONCOLOGY DAYS

## Collaboration for Good Practices with Patients (CGPP) Meeting

**June 22<sup>nd</sup>**  
Hotel International  
Brno

Lecture Hall A

Chair: *Dominique de Valeriola*  
and *Patrick Miqueu*

17.30-18.30 Topics will include:

**Exchange on the initiatives taking place in OECI centres to support Patient Involvement**

**Engage specific collaborations with ECPC (European Cancer Patient Coalition)**

**Frame the strategic plan of the CGPP WG**



© 360travel.cz

*Gala Dinner at Špilberk Castle - starting at 19.00 hours.*

Organisation  
of European  
Cancer Institutes

 **OEI** 2018

 **OEI40**

In collaboration with the



greater poland cancer centre

*Oncology Days*

**POZNAŃ 2018  
GENERAL ASSEMBLY,  
SCIENTIFIC CONFERENCES  
AND RELATED EVENTS**

**40<sup>th</sup>  
ANNIVERSARY  
OEI**



08.00 Registration

08.15 **General Assembly Constitution, welcome and approval of the Agenda**

Chairperson: *Dominique de Valeriola*

08.30 **Session 1: Administrative and financial matters**

Chairperson: *Dominique de Valeriola*

**Point 1: Oncology Days for the coming years**

**1.1: The 2018 Oncology Days - Poznan - Poland**

*Julian Malicki/Witold Cholewinski*

**1.2: Venues of the GAs after 2018**

*Dominique de Valeriola*

**Point 2: Approval of June 2016 General Assembly's Minutes**

(vote requested – decision taken at the simple majority of the OECI Full Members present or represented)

*Dominique de Valeriola*

**Point 3: Approval of the Financial Statement 2016 and discharge to the Board**

(vote requested - decision taken at simple majority of the OECI Full Members present or represented)

*José Laranja Pontes*

**Point 4: 2017 and 2018 Provisional Budget**

(the vote is requested only for 2017 budget – decision taken at simple majority of the OECI Full Members present or represented)

*José Laranja Pontes*

**Point 5: OECI Board composition for the coming years and proposal for President Elect**

(vote requested - decision taken at simple majority of the OECI Full Members present or represented)

*Dominique de Valeriola*

**Point 6: Working Groups and Co-opted Board Members update**

(vote not requested)

*Dominique de Valeriola*

**Point 7: OECI Membership**

*Claudio Lombardo*

**7.1 New applications for membership**

(vote requested for full membership - decision taken at unanimity of the OECI Full Members present or represented; for associated membership - decision taken by simple majority of the OECI Full Members present or represented)

**7.2 Requests of resignation from the OECI Membership**

(vote not requested)

**7.3 Change of denomination**

(vote not requested)



### CEREMONY FOR THE DELIVERY OF THE OECI ACCREDITATION CERTIFICATES 2017

*Dominique de Valeriola and Simon Oberst*



Centre Léon Bérard, Lyon

IRCCS Istituto Clinico Humanitas, Milano

Oslo Universitetssykehus (OUS), Oslo

Instituto Português de Oncologia do Porto Francisco Gentil E.P.E.  
(IPO-Porto), Porto



Masarykuv onkologický ústav, Brno

Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.  
(IPO-Lisboa), Lisbon

Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E.  
(IPO-Coimbra), Coimbra

10.45 *Coffee break*

11.00 **Session 2: The OECI Strategy and Working Group activities**

*Chairperson: Dominique de Valeriola*

#### **Point 8: Working Groups and Activities**

**8.1 First OECI-ECPC Pilot Project: Engaging Patients in Clinical research**

*Patrick Miqueu*

**8.2 Accreditation & Designation and the Joint Action on Rare Cancers**

*Simon Oberst*

**8.3 Biobanks and Molecular Pathobiology**

*Giorgio Stanta*

**8.4 Health Economics WG, COST application**

*Wim H. van Harten*

**8.5 OECI study proposal/feed-back of the survey on outcome studies**

*Milena Sant*

**Closure of the 2017 General Assembly**

*Dominique de Valeriola*

13.00 *Lunch*

13.30 **Departure 1<sup>st</sup> Bus to Vienna Airport** (arrival estimated at 16.00)

14.30 **Departure 2<sup>nd</sup> Bus to Vienna Airport** (arrival estimated at 17.00)

## Chairpersons and invited speakers

**Tit Albreht**

National Institute of Public Health – Ljubljana, Slovenia

**Serena Bonin**

Università degli Studi di Trieste, Italy

**Etienne Brain**

Institut Curie - Hôpital René-Huguenin de Saint-Cloud, France

**Witold Cholewinski**

Greater Poland Cancer Centre, Poznan, Poland

**Emanuele Crocetti**

European Commission, Health in Society Unit, Varese, Italy

**Francesco De Lorenzo**

European Cancer Patient Coalition, Brussels, Belgium

**Dominique de Valeriola**

Institut Jules Bordet, Brussels, Belgium

**Antionette de Vries**

Netherlands Comprehensive Cancer Organisation (IKNL), Nijmegen, The Netherlands

**Manfred Dietel**

Charité Comprehensive Cancer Centre, Berlin, Germany

**Ladislav Dušek**

Institute of Biostatistics and Analyses Masaryk University, Brno, Czech Republic

**Francesco Florindi**

European Cancer Patient Coalition, Brussels, Belgium

**Sophie Fossa**

Oslo University Hospital (OUH), Norway  
Gemma Gatta, Fondazione IRCCS-Istituto Nazionale Tumori, Milan, Italy

**Ivo Gut**

Centro Nacional de Analisis Genómico (CNAG), Barcelona, Spain

**Petr Holub**

Institute of Biostatistics and Analyses Masaryk University, Brno, Czech Republic

**Khayrullin Ildar**

Tatarstan Cancer Centre – Kazan, Russia Federation

**José Laranja Pontes**

Instituto Português de Oncologia do Porto, Portugal

**Ildar Khayrullin**

Tatarstan Cancer Center, Kazan, Russia

**Marialuisa Lavitrano**

University of Milano-Bicocca, Milan, Italy

**Jan Eric Litton**

Karolinska Institute and University Hospital, Stockholm, Sweden

**Claudio Lombardo**

Organisation of the European Cancer Institutes, Brussels, Belgium

**Julian Malicki**

Greater Poland Cancer Centre, Poznan, Poland

**Camille Maringe**

London School of Hygiene and Tropical Medicine, London, United Kingdom

**Patrick Miqueu**

Institut Jules Bordet, Brussels, Belgium

**Nicola Nicolai**

Fondazione IRCCS-Istituto Nazionale Tumori, Milan, Italy

**Simon Oberst**

Cambridge Cancer Centre (CRUK), Cambridge, United Kingdom

**Thierry Philip**

Institut Curie, Paris, France

**Marco Pierotti**

Fondazione IFOM - FIRC Institute of Molecular Oncology, Milan, Italy

**Milena Sant**

Fondazione IRCCS-Istituto Nazionale Tumori, Milan, Italy

**Giorgio Stanta**

Università degli Studi di Trieste, Italy

**Richard Sullivan**

King's Health Partners, London, United Kingdom

**Marek Svoboda**

Masaryk Memorial Cancer Institute, Brno, Czech Republic

**Annalisa Trama**

Fondazione IRCCS-Istituto Nazionale Tumori, Milan, Italy

**Luzia Travado**

Chamalimaud Clinical Center, Lisboa, Portugal

**Dalibor Valik**

Masaryk Memorial Cancer Institute, Brno, Czech Republic

**Wim H. van Harten**

Rijnstate Hospital, Arnhem, The Netherlands

**Rotislav Vyzula**

Masaryk Memorial Cancer Institute, Brno, Czech Republic

**Branko Zakotnik**

Institute of Oncology Ljubljana, Slovenia

**Jan Žaloudik**

Masaryk Memorial Cancer Institute, Brno, Czech Republic

**Gianluigi Zanetti**

Centro di ricerca, sviluppo e studi superiori in Sardegna (CRS4), Cagliari, Italy

## Sightseeing Tours

For trip booking and further information please contact: [jana.lounova@mou.cz](mailto:jana.lounova@mou.cz)

**Tuesday (June 20<sup>th</sup>) and Friday (June 23<sup>rd</sup>)**

### 1. The best of Brno City Centre

The group will be led by highly qualified tour guide. This walking tour takes about 2 hours.

Boarding at the entrance to the Hotel International at 2.00 p.m.

- Petrov – the Cathedral of St. Peter and Paul (Petrov)
- Vaclav Havel Street
- Cabbage Market (Zelný trh) with a large maze of underground tunnels, corridors and rooms and Parnas Fountain
- The Tale of a Built-in Councilman Haas
- The Brno Dragon and the Wheel Bet
- The twisted Pinnacle of the old town hall
- Freedom Square (náměstí Svobody) with the Clock Sculpture and Moravian Bank
- Indecent Little Man
- St. James' Square (Jakubské náměstí) with ossuary underneath the Church of St. James
- Leoš Janáček Theatre - Fountain
- The Avion Hotel - one of the narrowest hotels in Europe and others



## Sightseeing Tours

**Friday (June 23<sup>rd</sup>) and on request**

### 2. Mendel Museum

Boarding at the entrance to the Hotel International at 9.00 a.m. on Friday  
On request we can arrange another terms.

Mendel Museum is becoming an important point for the connection of science with practice and is a meeting place for the general public within an academic environment by combining the practical requirements of a museum and the theoretical subject.

You can visit the exhibition "Gregor Johann Mendel – the story of a humble genius."

This exhibition will show you father of genetics in a modern style and will introduce you Mendel as a personage of many interests. Thanks to the new technology of projecting pictures, important documents and videos and an oversized glass display, you will have an amazing opportunity to see not only the explanation of genetics in a different view but also the remote places where Mendel lived and worked during his life.



**Saturday (June 24<sup>th</sup>)**

### 3. Lednice – Mikulov – Valtice

1 day trip with lunch

(9.00 a.m. – 4.00 p.m.; Boarding at the Hotel International entrance)

Take a walk through the Garden of Europe in the Lednice-Valtice Complex!

There are not many places in the world which have received such care as the elegant area around the spectacular Lednice chateaux. An absolutely unique park has been created here over the centuries, full of rare tree species, romantic little buildings, fishponds and beautiful little corners. The Lednice-Valtice Complex, which has been included in the UNESCO list, is known as the Garden of Europe to this very day. Mikulov is a centre of Czech wine-making

due to its favorable geographic location and climate. Mikulov's historic buildings, such as Mikulov Castle, Dietrichstein sepulchre, the old Jewish Quarter, and the Piarist College, and the surrounding wine country draw tourists from the Czech Republic and neighboring countries. A part of trip will be a tasting of the finest Moravian wines.





## Sightseeing Tours


**Saturday (June 24<sup>th</sup>)**

### 4. Slavkov / Austerlitz

1 day trip with lunch

(9.00 a.m. – 3.00 p.m.; Boarding at the Hotel International entrance)

Follow Napoleon's footsteps to Slavkov! Slavkov u Brna is also known as Austerlitz. There are many places in the Czech Republic that have played a role in the development of European history. One that you definitely should not miss is Slavkov, just outside the Moravian capital of Brno. Not only will you find a splendid baroque castle with beautiful gardens here but also the setting of one of Europe's most famous battles. Take a trip back in time and experience the gripping story of the three emperors who in December 1805 faced off in a bloody battle here.





In collaboration with



**MONKIN**  
Moravian Oncology Initiative

## THE OEI 2017 SCIENTIFIC COMMITTEE

### Presidents

Dominique de Valeriola

### Members

Carlos Caldas, Riccardo Capocaccia, Gemma Gatta,  
José Laranja Pontes, Claudio Lombardo, József Lövey,  
Marco A. Pierotti, Thierry Philip, Gunnar Sæter, Milena Sant,  
Giorgio Stanta, Marek Švoboda, Dalibor Valík, Wim van Harten,  
Christof von Kalle, Jan Žaloudík

## THE OEI 2017 LOCAL ORGANISING COMMITTEE

### President

Jan Žaloudík, Masaryk Memorial Cancer Institute, Brno

### Members

Ladislav Dušek, Institute of Biostatistics and Analyses, Brno  
Marek Švoboda, Masaryk Memorial Cancer Institute, Brno  
Dalibor Valík, Masaryk Memorial Cancer Institute / Czech  
BBMRI, Brno

Rostislav Vyzula, Masaryk Memorial Cancer Institute, Brno

### Secretariat

Radka Babáková, Eva Cechmanová, Jana Lounová  
Masaryk Memorial Cancer Institute, Brno

### Contact

Phone +420 54313 4102

E-mail: [direct@mou.cz](mailto:direct@mou.cz)

## THE OEI 2017 ONCOLOGY DAYS SECRETARIATS

BRUSSELS: Maria Cummins, Lutgarde D'Hauwers

GENOA: Giorgia Pesce, Patrizia Sommella

TRIESTE: Valentina Melita

## OEI 2017 ONCOLOGY DAYS COORDINATING OFFICE

Claudio Lombardo - OEI Director

Phone +32 2 512 01 46

E-mail: [oei@oei.eu](mailto:oei@oei.eu)

[www.oei.eu](http://www.oei.eu)

Recommended by

